ArticleJournal of thoracic disease2025
Survival prognosis and clinical experience of HeartCon-type left ventricular assist device implantation for treating patients with end-stage heart failure: a single-center retrospective study from China.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Escalating rates of heart failure (HF) cases across the globe show a strong correlation with progressive population aging trends. Therefore, we investigated the survival prognosis, safety and efficacy of the Chinese domestically produced HeartCon-type left ventricular assist device (LVAD) in treating patients with end-stage heart failure (ESHF) and share some clinical experience through a single-center retrospective study. Methods: Retrospective consecutive data of 36 ESHF patients who were successfully implanted with HeartCon-type LVAD, were included to analyze postoperative complications and survival prognosis. The patients were postoperatively followed up for endpoint events, including death, heart transplantation (HTx), pump removal, pump replacement, and continuous survival with pump. Patient survival was calculated at 90 days, 6 months, 1 year, and 2 years after LVAD implantation, respectively. Results: Baseline characteristics included a mean age of 49.2±14.8 years, 58.3% male. The follow-up time was 620±376 days. Survival rates at 90 days, 6 months, 1 year, and 2 years after LVAD implantation were 94%, 94%, 91%, and 91%, respectively. There were 5 deaths (5/36, 13.9%), 1 HTx (1/36, 2.8%), 2 pump removals (2/36, 5.6%), 1 pump replacement (1/36, 2.8%), and 28 patients (28/36, 77.8%) were alive with continued pump support at follow up. Conclusions: The study indicates that the domestically produced HeartCon-type LVAD in China has a definite, satisfactory therapeutic effect in the treatment of ESHF, which provides a new effective and safe treatment option for ESHF patients that allows quality of life improvement, successful bridging to HTx, and potential long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.